Christopher Korban

WORK HISTORY

EDUCATION

ABOUT CHRISTOPHER KORBAN

I am the Co-Founder and CEO of Revilico Inc where we\'re pioneering the development of an AI-driven end to end operating system for small molecule drug discovery. I have directly contributed to the advancement of molecular modeling strategies, algorithm development, and model builds across verticals in ligand protein binding chemistries, quantum chemistry algorithms using Density Functional Theory (DFT), Machine Learning Interatomic Potentials, and Neural Network Potentials, multi-omic analytics, and virtual cell modeling that evaluates compound perturbations of gene expression, and integration of experimental orchestration strategies for laboratory testing. My efforts have led to over compounds screened for incurable genetic disorders, several development candidates across oncology, immunology, and longevity, and predictive and generative models to drive the field of computational drug discovery forward. My work has directly contributed to a 10x reduction in experimental waste, and a 20x multiplier on the hit rates observed in high throughput screening using computational-experimental dual strategies across Pharma.I did my training at UCLA, where I conducted research across multiple fields. At the UCLA Molecular Screening Shared Resource (MSSR) with Dr. Robert Damoiseaux, I contributed to high-throughput screening campaigns of compounds for the discovery of novel therapeutic candidates using compound library selection, robotic automation, liquid handling, cell culture, and cell imaging for indications in incurable genetic disorders. I was primarily involved with the development of computational simulation strategies, microscopy imaging and analysis, and medicinal chemistry design and execution for hit validation and structure activity optimizations. At the Di Carlo Lab, I investigated AI enabled point-of-care technologies and diagnostic devices. In the I2BL Lab, I developed biomarker and metabolite biosensors using electrochemical sensing techniques for implantable and wearable applications for post-operation liver monitoring using engineered and immobilized enzymes. As part of the Wright Lab, I was focused on compound synthesis and protein polymer bioconjugation strategies for polymersome drug delivery systems intended for cancer and diabetes treatment, advancing understanding of thermodynamic drivers of protein structure, delivery, and activity.